Effects of formoterol on exercise tolerance in severely disabled patients with COPD

Respiratory Medicine

Volumn 101, Issue 10, 2007, Pages 2056-2064

  Neder, J Alberto ^a   Fuld, Jonathan P ^b   Overend, Tim ^c   Thirlwell, Jackie ^c   Carter, Roger ^d   Stevenson, Robin ^d   Ward, Susan A ^e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Dynamic hyperinflation; Dyspnoea; Exercise testing; Formoterol; Inspiratory capacity

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; THEOPHYLLINE; THEOPHYLLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BICYCLE ERGOMETER; BICYCLE ERGOMETRY; BRONCHODILATATION; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; INSPIRATORY RESERVE VOLUME; LUNG FUNCTION TEST; MALE; METERED DOSE INHALER; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TIDAL VOLUME;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHODILATOR AGENTS; DISABLED PERSONS; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC STUDIES; ETHANOLAMINES; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 34548279878     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.06.006     Document Type: Article

References (48)

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005. At: 〈http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989〉 (accessed 21 November 2005).
2. Ries A.L., Kaplan R.M., Limberg T.M., and Prewitt L.M. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 122 (1995) 823-832
3. Gerardi D.A., Lovett L., Benoit-Connors M.L., Reardon J.Z., and ZuWallack R.L. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9 (1996) 431-435
4. Belman M.J., Botnick W.C., and Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153 (1996) 967-975
5. O'Donnell D.E., Lam M., and Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 (1998) 1557-1565
6. O'Donnell D.E., Revill S.M., and Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 770-777
7. Boni E., Corda L., Franchini D., et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 57 (2002) 528-532
8. Stubbing D.G., Pengelly L.D., Morse J.L., and Jones N.L. Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. J Appl Physiol 49 (1980) 511-515
9. O'Donnell D.E., and Webb K.A. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 148 (1993) 1351-1357
10. Somfay A., Porszasz J., Lee S.M., and Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 18 (2001) 77-84
11. Porszasz J., Emtner M., Goto S., Whipp B.J., and Casaburi R. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 128 (2005) 2025-2034
12. Palange P., Valli G., Onorati P., et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 97 (2004) 1637-1642
13. O'Donnell D.E., Voduc N., Fitzpatrick M., and Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24 (2004) 86-94
14. O'Donnell D.E., Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
15. O'Donnell D.E., Lam M., and Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) 542-549
16. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 52 (1993) 2145-2160
17. Dahl R., Greefhorst L.A., Nowak D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 778-784
18. Rossi A., Kristufek P., Levine B.E., et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121 (2002) 1058-1069
19. Aalbers R., Ayres J., Backer V., et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 19 (2002) 936-943 Erratum in: Eur Respir J 2002;20:245
20. Liesker J.J., Van De Velde V., Meysman M., et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med 96 (2002) 559-566
21. Oga T., Nishimura K., Tsukino M., Hajiro T., Ikeda A., and Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Respir Crit Care Med 161 (2000) 1897-1901
22. Van't Hul A., Gosselink R., and Kwakkel G. Constant-load cycle endurance performance: test-retest reliability and validity in patients with COPD. J Cardiopulm Rehabil 23 (2003) 143-150
23. Celli B. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 3 (2006) 58-65
24. 2-agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. BMC Pulm Med 4 (2004) 7
25. 2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3 (2006) CD001104
26. Mahler D.A., Weinberg D.H., Wells C.K., and Feinstein A.R. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
27. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl 16 (1993) 5-40
28. Borg G.A.V. Psychophysical bases of perceived exertion. Med Sci Sports Exercise 14 (1982) 377-381
29. Buchfuhrer M.J., Hansen J.E., Robinson T.E., Sue D.Y., Wasserman K., and Whipp B.J. Optimizing the exercise protocol for cardiopulmonary assessment. J Appl Physiol 55 (1983) 1558-1564
30. Neder J.A., Nery L.E., Castelo A., et al. Prediction of metabolic and cardiopulmonary responses to maximum cycle ergometry: a randomised study. Eur Respir J 14 (1999) 1304-1313
31. Buchfuhrer M.J., Hansen J.E., Robinson T.E., Sue D.Y., Wasserman K., and Whipp B.J. Optimizing the exercise protocol for cardiopulmonary assessment. J Appl Physiol 55 (1983) 1558-1564
32. Koch G.G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28 (1972) 577-584
33. Conover W.J. The Hodges-Lehmann estimator. Practical nonparametric statistics. 3rd ed (1982), Wiley, New York 282
34. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2005) 948-968
35. Albuquerque A, Nery LE, Villaca DS, Machado T, Oliveira CC, Paes AT, et al. Inspiratory fraction (IC/TLC) and exercise impairment in COPD patients GOLD stages II-III. Eur Respir J; 2006, July 26 [Epub ahead of print].
36. American thoracic society and American college of chest physicians. Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-77.
37. Calverley P.M., Burge P.S., Spencer S., Anderson J.A., and Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58 (2003) 659-664
38. O'Donnell D.E., Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
39. Maltais F., Hamilton A., Marciniuk D., et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128 (2005) 1168-1178
40. O'Donnell D.E., Sciurba F., Celli B., Mahler D.A., Webb K.A., Kalberg C.J., et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130 (2006) 647-656
41. Calverley P.M. Breathlessness during exercise in COPD: how do the drugs work?. Thorax 59 (2004) 455-457
42. Neder J.A., Jones P.W., Nery L.E., and Whipp B.J. Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease. The power-duration relationship. Am J Respir Crit Care Med 162 (2000) 497-504
43. Puente-Maestu L., Santa Cruz A., Vargas T., Martinez-Abad Y., and Whipp B.J. Effects of training on the tolerance to high-intensity exercise in patients with severe COPD. Respiration 70 (2003) 367-370
44. Palange P., Ward S.A., Carlsen K.-H., Casaburi R., Gallagher C.G., Gosselink R., et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 29 (2007) 185-209 (online supplement)
45. Pepin V., Saey D., Whittom F., LeBlanc P., and Maltais F. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005) 1517-1522
46. Grove A., Lipworth B.J., Reid P., et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 51 (1996) 689-693
47. Man W.D., Mustfa N., Nikoletou D., et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 59 (2004) 471-476
48. Corsico A., Fulgoni P., Beccaria M., et al. Effects of exercise and beta 2-agonists on lung function in chronic obstructive pulmonary disease. J Appl Physiol 93 (2002) 2053-2058